Published • loading... • Updated
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Summary by Globe Newswire
7 Articles
7 Articles
Globe Newswire+6 Reposted by 6 other sources
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Media ReleaseCOPENHAGEN, Denmark; June 13, 2026 Results from the Phase 2 EPCORE® DLBCL-3 trial show fixed-duration epcoritamab monotherapy demonstrated...
Coverage Details
Total News Sources7
Leaning Left2Leaning Right0Center1Last UpdatedBias Distribution67% Left
Bias Distribution
- 67% of the sources lean Left
67% Left
L 67%
C 33%
Factuality
To view factuality data please Upgrade to Premium
